Cavalier Jason
SEC insider (Form 3/4/5 filer). CIK 0001883290. Principal Financial Officer at Lyra Therapeutics, Inc. (LYRA). 5 reported Form 4/5 transactions since Sep 2024; latest on Apr 1, 2026. Located in WATERTOWN, MA.
Companies Cavalier Jason has filed insider reports for
- Lyra Therapeutics, Inc. (LYRA): Officer, Principal Financial Officer
Cavalier Jason
CIK: 0001883290
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (40.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (40.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (20.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LYRA
Lyra Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Apr 1, 2026LYRA
Lyra Therapeutics, Inc.
DispositionDirect667 shares- - Jan 6, 2026LYRA
Lyra Therapeutics, Inc.
SaleDirect769 shares at avg. $3.36$3K - Jul 10, 2025LYRA
Lyra Therapeutics, Inc.
SaleDirect684 shares at avg. $8.91$6K - Jan 8, 2025LYRA
Lyra Therapeutics, Inc.
AwardDirect420K shares- - Oct 16, 2024LYRA
Lyra Therapeutics, Inc.
AwardDirect100K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 1, 2026 | LYRA Lyra Therapeutics, Inc. | Disposition | 667 | - | $0 | Direct |
| Jan 6, 2026 | LYRA Lyra Therapeutics, Inc. | Sale | 769 | $3.36 | $2,587 | Direct |
| Jul 10, 2025 | LYRA Lyra Therapeutics, Inc. | Sale | 684 | $8.91 | $6,094 | Direct |
| Jan 8, 2025 | LYRA Lyra Therapeutics, Inc. | Award | 420,000 | - | $0 | Direct |
| Oct 16, 2024 | LYRA Lyra Therapeutics, Inc. | Award | 100,000 | - | $0 | Direct |
1-5 of 5 transactions